Part D: Patients must have measurable disease for Part D
Patients must have measurable disease
Measurable disease
Re-registration: measurable disease
Measurable disease
Patients must have measurable disease
Patients must have measurable disease
Documented metastatic disease (may be measurable or non-measurable)
Subjects must have measurable disease.
Measurable disease
Subjects with measurable disease.
Patients may have either non-measurable disease OR measurable disease
Have measurable disease
Patients must have at least one measurable site of disease
Measurable disease or non-measurable disease and refractory to or intolerant of existing therapies (Part 1)
Measurable disease
Part B: Patients must have measurable disease
Patients who do not have measurable disease on MRI
Measurable disease
Presence of measurable disease.
Measurable metastatic disease.
Patients must have measurable disease
Measurable disease
Patients must have measurable disease
Phase 1: patients may have measurable or non-measurable disease; measurable disease via RECIST 1.1 is required for Phase 2 patients
Measurable disease
Subjects must have measurable disease
Patients must have measurable disease.
Measurable disease
Measurable disease
Patients must have measurable disease
Must have measurable disease defined by:
Measurable disease
Subjects must have measurable disease
Measurable disease
Measurable disease in at least one site
Presence of measurable disease:
Measurable disease
Subjects with measurable or non-measurable lesions.
PHASE I: Patients may have measurable or non-measurable disease
Non-measurable disease only
Patients who have no measurable disease
Measurable disease or non measurable disease bone lesions in the absence of measurable disease as per RECIST 1.1
Measurable disease
Measurable disease
Measurable disease;
Measurable disease
Measurable disease.
Measurable disease
Measurable or non-measurable metastatic disease
Patient has measurable disease.
Patients must have at least one site of measurable disease
Measurable disease
Measurable disease
Measurable disease
Patients must have measurable disease
Measurable disease
Measurable disease
Measurable disease
Measurable disease required
Patients must have measurable disease
Measurable disease
Measurable disease
Has measurable disease
Measurable disease
Patients must have either measurable or evaluable limited-stage DLBCL          \r\n* Patients rendered free of measurable or evaluable disease by virtue of biopsy (resection) are also eligible; NOTE: if patient has measurable disease it must be documented on the Lymphoma Baseline Tumor Assessment Form\r\n* All measurable disease must be assessed within 28 days prior to registration\r\n* Patients with non-measurable disease with or without measurable disease must have all non-measurable disease assessed within 42 days prior to registration
Patients must have measurable disease
Has measurable disease
Subjects must have measurable disease
Subjects must have measurable disease
Measurable disease at time of enrollment
Measurable disease
Has measurable disease.
Measurable disease at screening
Must have measurable disease
Patient must have measurable disease or detectable (non-measurable) disease: Measurable disease will be defined by RECIST 1.1.
Measurable disease criteria:
Measurable disease
Measurable or non-measurable disease will be allowed, but only those with measurable disease will be evaluable for the response rate endpoint
Measurable disease
Measurable disease
Patients must have measurable disease
Participant has measurable and/or non-measurable disease
Measurable disease, requiring treatment
Both measurable as well as non-measurable disease will be allowed
Measurable disease
Patients must have measurable disease
Measurable disease
Measurable disease: measurable by gadolinium MRI scan
Measurable or non-measurable disease
Measurable disease
Measurable disease
Measurable disease
Measurable or non-measurable disease
Non-measurable or measurable disease
Measurable disease; note: disease that is measurable by physical examination only is not eligible
The patient has measurable disease
Measurable and non-measurable disease will be allowed
Patients must have measurable disease
Patients must have measurable disease at baseline
Measurable disease at the time of enrollment
Measurable disease
Patients may have measurable or non-measurable disease. x-rays and/or scans for disease assessment of measurable disease must have been completed within 28 days prior to registration; non-measurable disease must also be assessed within 28 days prior to registration; (expansion – patients must have measurable disease)
Patients may have measurable or non-measurable disease; x-rays and/or scans for disease assessment of measurable disease must have been completed within 28 days prior to registration; non-measurable disease must also be assessed within 28 days prior to registration
Measurable disease
Patients must have measurable disease, defined as at least one tumor that is measurable
Measurable or non-measurable disease will be allowed
Subjects must have measurable disease
Measurable disease
Patients must have measurable disease:
Presence of measurable disease
Both measurable and non-measurable disease are allowed
Measurable disease
Measurable or non-measurable disease
Have measurable disease.
Measurable disease
Measurable disease;
Patients with measurable and non-measurable disease are eligible. Patients may or may not have cancer-related symptoms.
Participants do not need to have measurable disease; most patients will not have measurable disease at the time of treatment
Presence of measurable disease
Measurable disease
Patients must have disease that can be evaluated radiographically; this may be measurable disease or non-measurable disease; measurable disease is defined as that which can be measured in at least one dimension as >= 20 mm with conventional techniques, or >= 10 mm by high resolution imaging; disease that is identified on radiology studies, but does not meet the criteria for measurable disease, is considered non-measurable
Measurable disease
At least 1 measurable site of disease
Measurable disease.
Must have measurable disease defined as:
Must have measurable disease for Part A, measurable disease or non-measurable disease for Part B
Measurable or non-measurable disease will be allowed
Measurable tumor
Non-measurable or measurable, metastatic disease
Patients must have measurable disease
Patients may have either non-measurable disease OR measurable disease
Measurable disease
Measurable or non-measurable disease
Measurable disease
Measurable disease
Only evidence of disease is non-measurable.
Measurable or non-measurable disease
Patients must have measurable disease
May have measurable disease, non-measurable disease, or both.
Measurable disease
Measurable disease
Measurable or non-measurable disease that has progressed since last treatment.
Measurable disease
Measurable disease
Measurable or non-measurable disease
Patients must have measurable disease (Phase I)
Measurable disease
Patients must have measurable disease
Presence of measurable or non-measurable disease.
Measurable disease
Disease may be measurable or non-measurable
Measurable disease
At least one site of measurable disease
Measurable disease
Subjects must have measurable disease
Measurable disease.
Patients who only have non-measurable disease
Measurable Disease:
Measurable or non-measurable disease will be allowed
The participant has measurable or non-measurable disease.
Presence of measurable disease
Confirmed measurable disease